This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

John Wiley & Sons' CEO Discusses F1Q 2012 Results - Earnings Conference Call

John Wiley & Sons, Inc (JW.A)

F1Q 2011 Earnings Call Transcript

September 8, 2012, 10:00 am ET

Executives

Steve Smith - President, CEO

Ellis Cousens - EVP, CFOO

Analysts

Drew Crum - Stifel Nicolaus

Dave Lewis - JPMorgan

Torin Eastburn - EPS Securities

Michael Corty - Morningstar

Ian Whittaker - Liberum Capital

Presentation

Operator

Welcome to the John Wiley & Sons quarterly earnings call. Before introducing Steve Smith, President and Chief Executive Officer, I would like to remind you this call is being recorded and may include forward-looking statements.

You should not rely on such statements as actual results may differ materially and are subject to factors that are discussed in detail in the company's 10-K and 10-Q filings with the SEC.

The company does not undertake any obligations to update or revise forward-looking statements to reflect subsequent events or circumstances. Mr. Smith, please go ahead.

Steve Smith

Good morning and thank you for participating in Wiley's fiscal year 2012 first quarter investor conference call. I'm with Ellis Cousens, Executive Vice President and Chief Financial Operations Officer; and Brian Campbell, Director of Investor Relations.

I'll take a few moments to write an overview of Wiley's performance in the first quarter and we will then respond to your comments and questions. Before I do so, however, I'd like to draw your attention to an 8-K statement filed on Tuesday concerning my health in which we announced that I am being treated for urologic cancer.

I have been treated surgically to remove all detectable tumor cells. I am now undergoing chemotherapy treatment to ensure that no cancer cells remain in my system. My doctor has advised that the prognosis is good for a full recovery and I expect to continue working through my treatment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs